ECOG-ACRIN Cancer Research Group clinical trials
Listed in the registry as: Research network.
The registry lists 121 studies whose lead sponsor is ECOG-ACRIN Cancer Research Group. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the ECOG-ACRIN Cancer Research Group studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions ECOG-ACRIN Cancer Research Group leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 121. Browse all 121 →
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityRecruitingNCT07001748Phase 2/3
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingNCT07852195Phase 2/3
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerRecruitingNCT06475989Phase 3
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingNCT05863195Phase 3
- Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage MelanomaRecruitingNCT07068074Phase 3
- Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of MelanomaRecruitingNCT07040280Phase 2
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryRecruitingNCT02734537Phase 2
- Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated BiomarkersRecruitingNCT04239573
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaRecruitingNCT03937635Phase 3
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingNCT04566328Phase 3
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingNCT04423211Phase 3
- Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE TrialRecruitingNCT06319027Phase 2
- Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07765433Phase 2/3
- Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue SarcomaNot yet recruitingNCT06526897Not applicable
- Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast CancerActive, not recruitingNCT03233191Phase 3
- Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE StudyActive, not recruitingNCT04316117Phase 2
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE StudyActive, not recruitingNCT04166318Phase 2
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruitingNCT04266249Phase 2
- Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the BodyActive, not recruitingNCT04248452Phase 3
- Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder CancerActive, not recruitingNCT04559139Phase 2/3
- Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT TrialActive, not recruitingNCT05710328Phase 2
- Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03504644Phase 1/2
- Reproductive Health Program in Patients With CancerActive, not recruitingNCT01806129Not applicable
- Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerActive, not recruitingNCT04001829Phase 2
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelActive, not recruitingNCT03419234Phase 2
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K MelanomaTerminatedNCT04527549Phase 2
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedNCT04221438Phase 2
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT01863550Phase 3
- Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyActive, not recruitingNCT02445391Phase 3
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine CarcinomasActive, not recruitingNCT02595424Phase 2
- Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory PneumonitisTerminatedNCT04438382Phase 2
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaCompletedNCT00003641Phase 3
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT01824875Phase 2
- Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentActive, not recruitingNCT03516942
- Cancer and Blood Pressure Management, CARISMA StudyActive, not recruitingNCT04467021Not applicable
- Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate CancerActive, not recruitingNCT03697148Not applicable
- Intravesical BCG vs GEMDOCE in NMIBCActive, not recruitingNCT05538663Phase 3
- Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community SettingWithdrawnNCT03804255
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialActive, not recruitingNCT04462406Phase 2
- Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR StudyActive, not recruitingNCT05863351Phase 3
- Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer SurvivorsActive, not recruitingNCT06002828
- DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent GlioblastomaActive, not recruitingNCT03115333Not applicable
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT04115631Phase 2
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by SurgeryActive, not recruitingNCT03493425Phase 2
- Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT05721755Phase 3
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionActive, not recruitingNCT03267433Phase 3
- Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)Active, not recruitingNCT06295367Not applicable
- Mobile Health for Adherence in Breast Cancer PatientsActive, not recruitingNCT06112613Not applicable
- To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringActive, not recruitingNCT04597359Phase 2